HER 2 NEGATIVE BREAST CANCER
Clinical trials for HER 2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER 2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER 2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough breast cancer: Two-Drug combo targets resistant tumors
Disease control Recruiting nowThis study tests a combination of two drugs, eribulin and anlotinib, in 52 women with HER2-negative advanced breast cancer whose disease has worsened after prior treatments like antibody-drug conjugates. The goal is to see if the combo can slow cancer growth and improve survival.…
Matched conditions: HER 2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 17, 2026 04:29 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis study is testing a combination of two drugs, utidelone and bevacizumab, in people with advanced HER-2 negative breast cancer who have already tried at least two other treatments. The goal is to see if this combination can slow down the cancer's growth and improve outcomes. A…
Matched conditions: HER 2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 08, 2026 13:16 UTC